Les campanyes de vacunació front al virus de la grip aviària, són eficaces?

Durant les últimes dècades s'han detectat brots de grip aviària causants d'una elevada mortalitat en aus, tant domèstiques com salvatges. La presència de virus de la influença (o grip) aviària d'alta patogenicitat (IAAP) suposa un risc elevat per l'economia i per la sanitat animal i humana. Per intentar prevenir i/o controlar futures epidèmies cal disposar de programes de control i vigilància del virus i de campanyes de vacunació adequades. Un estudi publicat recentment a la revista Clinical and Vaccine Immunology en el que han participat investigadors del Centre de Recerca en Sanitat Animal (CReSA), ha permès avaluar l'èxit de les campanyes de vacunació dutes a terme entre el 2006 i el 2008. Les dades es van recopilar dins un programa coordinat per l'Asociación Ibérica de Zoos y Acuarios i el Ministerio de Medio Ambiente y Medio Rural y Marino per avaluar l'eficàcia de la vacunació.Several avian influenza outbreaks have been reported to be responsible of high mortality in both domestic and wild birds. Highly pathogenic avian influenza (HPAI) viruses are a threat to the economy and animal and human health. Vaccination campaigns, together with good surveillance programs, are an important key to prevent and control future outbreaks. Researchers from Centre de Recerca en Sanitat Animal (CReSA) participated in a study published in Clinical and Vaccine Immunology with the objective to evaluate two vaccination campaigns carried out between 2006 and 2008. Data were collected during a program coordinated by the Iberic Association of Zoos and Aquariums (Asociación Ibérica de Zoos y Acuarios) and the Spanish Government to assess the efficacy of vaccination.Durante las últimas décadas se han detectado brotes de gripe aviar causantes de una elevada mortalidad en aves, tanto domésticas como salvajes. La presencia de virus de la influenza (o gripe) aviar de alta patogenicidad (IAAP) supone un riesgo elevado para la economía y para la sanidad animal y humana. Para intentar prevenir y / o controlar futuras epidemias es necesario disponer de programas de control y vigilancia del virus y de campañas de vacunación adecuadas. Un estudio publicado recientemente en la revista Clinical and Vaccine Immunology en el que han participado investigadores del Centro de Investigación en Sanidad Animal (CReSA), ha permitido evaluar el éxito de las campañas de vacunación llevadas a cabo entre 2006 y 2008. Los datos se recopilaron en un programa coordinado por la Asociación Ibérica de Zoos y Acuarios y el Ministerio de Medio Ambiente y Medio Rural y Marino para evaluar la eficacia de la vacunación

Zoonotic diseases: Can the transmission of pathogens between animals and humans be controlled?

After being associated with more than six million deaths so far, the Covid-19 pandemic is one of the worst diseases of animal origin known to date. Other zoonotic diseases such as severe acute respiratory syndrome (2002–2004, which mainly affected China), Middle East respiratory syndrome (2012, mainly affecting the Middle East), Ebola (2013–2016 in West Africa), and Rift Valley fever (from 2016 to the present) have also caused major disease outbreaks in recent decades. In addition, and especially in low-income countries, some zoonotic diseases such as tuberculosis and rabies are endemic and cause thousands of deaths. Of note, up to 60 % of known infectious diseases and 75 % of emerging infectious diseases have an animal origin and are responsible for public health problems and economic losses.info:eu-repo/semantics/publishedVersio

Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target [version 1; peer review: awaiting peer review]

A novel coronavirus recently identified in Wuhan, China (2019-nCoV) has expanded the number of highly pathogenic coronaviruses affecting humans. The 2019-nCoV represents a potential epidemic or pandemic threat, which requires a quick response for preparedness against this infection. The present report uses the informational spectrum methodology to identify the possible origin and natural host of the new virus, as well as putative therapeutic and vaccine targets. The performed in silico analysis indicates that the newly emerging 2019-nCoV is closely related to severe acute respiratory syndrome (SARS)-CoV and, to a lesser degree, Middle East respiratory syndrome (MERS)-CoV. Moreover, the well-known SARS-CoV receptor (ACE2) might be a putative receptor for the novel virus as well. Additional results indicated that civets and poultry are potential candidates for the natural reservoir of the 2019-nCoV, and that domain 288-330 of S1 protein from the 2019-nCoV represents promising therapeutic and/or vaccine target.info:eu-repo/semantics/publishedVersio

Enhanced antiviral immunity and dampened inflammation in llama lymph nodes upon MERS-CoV sensing: bridging innate and adaptive cellular immune responses in camelid reservoirs

Middle East respiratory syndrome coronavirus (MERS-CoV) infection can cause fatal pulmonary inflammatory disease in humans. Contrarily, camelids and bats are the main reservoir hosts, tolerant for MERS-CoV replication without suffering clinical disease. Here, we isolated cervical lymph node (LN) cells from MERS-CoV convalescent llamas and pulsed them with two different viral strains (clades B and C). Viral replication was not supported in LN, but a cellular immune response was mounted. Reminiscent Th1 responses (IFN-γ, IL-2, IL-12) were elicited upon MERS-CoV sensing, accompanied by a marked and transient peak of antiviral responses (type I IFNs, IFN-λ3, ISGs, PRRs and TFs). Importantly, expression of inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8) or inflammasome components (NLRP3, CASP1, PYCARD) was dampened. The role of IFN-λ3 to counterbalance inflammatory processes and bridge innate and adaptive immune responses in camelid species is discussed. Our findings shed light into key mechanisms on how reservoir species control MERS-CoV in the absence of clinical disease.This study was performed as part of the Zoonotic Anticipation and Preparedness Initiative (ZAPI) [Innovative Medicines initiative (IMI) grant 115760] and the Veterinary Biocontained research facility Network (VetBioNet) (EU Grant Agreement INFRA-2016-1 N°731014) projects, with assistance and financial support from IMI and the European Commission and contributions from EFPIA partners. JR was partially supported by the VetBioNet. IRTA is supported by CERCA Programme/Generalitat de Catalunya.info:eu-repo/semantics/publishedVersio

Animal models to study the neurological manifestations of the post-COVID-19 condition

More than 40% of individuals infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have experienced persistent or relapsing multi-systemic symptoms months after the onset of coronavirus disease 2019 (COVID-19). This post-COVID-19 condition (PCC) has debilitating effects on the daily life of patients and encompasses a broad spectrum of neurological and neuropsychiatric symptoms including olfactory and gustative impairment, difficulty with concentration and short-term memory, sleep disorders and depression. Animal models have been instrumental to understand acute COVID-19 and validate prophylactic and therapeutic interventions. Similarly, studies post-viral clearance in hamsters, mice and nonhuman primates inoculated with SARS-CoV-2 have been useful to unveil some of the aspects of PCC. Transcriptomic alterations in the central nervous system, persistent activation of immune cells and impaired hippocampal neurogenesis seem to have a critical role in the neurological manifestations observed in animal models infected with SARS-CoV-2. Interestingly, the proinflammatory transcriptomic profile observed in the central nervous system of SARS-CoV-2-inoculated mice partially overlaps with the pathological changes that affect microglia in humans during Alzheimer's disease and aging, suggesting shared mechanisms between these conditions. None of the currently available animal models fully replicates PCC in humans; therefore, multiple models, together with the fine-tuning of experimental conditions, will probably be needed to understand the mechanisms of PCC neurological symptoms. Moreover, given that the intrinsic characteristics of the new variants of concern and the immunological status of individuals might influence PCC manifestations, more studies are needed to explore the role of these factors and their combinations in PCC, adding further complexity to the design of experimental models. In this Perspective, the authors summarize the current knowledge on the post-COVID-19 condition, focusing on the neurological manifestations, and discuss the applicability of existing animal models to recapitulate human condition

Enhanced replication fitness of MERS-CoV clade B over clade A strains in camelids explains the dominance of clade B strains in the Arabian Peninsula

Middle East respiratory syndrome coronavirus (MERS-CoV) continues infecting humans and dromedary camels. While MERS-CoV strains from the Middle East region are subdivided into two clades (A and B), all the contemporary epidemic viruses belong to clade B. Thus, MERS-CoV clade B strains may display adaptive advantages over clade A in humans and/or reservoir hosts. To test this hypothesis in vivo, we compared an early epidemic clade A strain (EMC/2012) with a clade B strain (Jordan-1/2015) in an alpaca model monitoring virological and immunological parameters. Further, the Jordan-1/2015 strain has a partial amino acid (aa) deletion in the double-stranded (ds) RNA binding motif of the open reading frame ORF4a protein. Animals inoculated with the Jordan-1/2015 variant had higher MERS-CoV replicative capabilities in the respiratory tract and larger nasal viral shedding. In the nasal mucosa, the Jordan-1/2015 strain caused an early IFN response, suggesting a role for ORF4a as a moderate IFN antagonist in vivo. However, both strains elicited maximal transcription of antiviral interferon-stimulated genes (ISGs) at the peak of infection on 2 days post inoculation, correlating with subsequent decreases in tissular viral loads. Genome alignment analysis revealed several clade B-specific amino acid substitutions occurring in the replicase and the S proteins, which could explain a better adaptation of clade B strains in camelid hosts. Differences in replication and shedding reported herein indicate a better fitness and transmission capability of MERS-CoV clade B strains than their clade A counterparts

Searching for animal models and potential target species for emerging pathogens : Experience gained from Middle East respiratory syndrome (MERS) coronavirus

Emerging and re-emerging pathogens represent a substantial threat to public health, as demonstrated with numerous outbreaks over the past years, including the 2013-2016 outbreak of Ebola virus in western Africa. Coronaviruses are also a threat for humans, as evidenced in 2002/2003 with infection by the severe acute respiratory syndrome coronavirus (SARS-CoV), which caused more than 8000 human infections with 10% fatality rate in 37 countries. Ten years later, a novel human coronavirus (Middle East respiratory syndrome coronavirus, MERS-CoV), associated with severe pneumonia, arose in the Kingdom of Saudi Arabia. Until December 2016, MERS has accounted for more than 1800 cases and 35% fatality rate. Finding an animal model of disease is key to develop vaccines or antivirals against such emerging pathogens and to understand its pathogenesis. Knowledge of the potential role of domestic livestock and other animal species in the transmission of pathogens is of importance to understand the epidemiology of the disease. Little is known about MERS-CoV animal host range. In this paper, experimental data on potential hosts for MERS-CoV is reviewed. Advantages and limitations of different animal models are evaluated in relation to viral pathogenesis and transmission studies. Finally, the relevance of potential new target species is discussed

Evaluation of alpaca tracheal explants as an ex vivo model for the study of Middle East respiratory syndrome coronavirus (MERS-CoV) infection

Altres ajuts: China Scholarship Council 201608150108Middle East respiratory syndrome coronavirus (MERS-CoV) poses a serious threat to public health. Here, we established an ex vivo alpaca tracheal explant (ATE) model using an air-liquid interface culture system to gain insights into MERS-CoV infection in the camelid lower respiratory tract. ATE can be infected by MERS-CoV, being 103 TCID50/mL the minimum viral dosage required to establish a productive infection. IFNs and antiviral ISGs were not induced in ATE cultures in response to MERS-CoV infection, strongly suggesting that ISGs expression observed in vivo is rather a consequence of the IFN induction occurring in the nasal mucosa of camelids

Evaluation of alpaca tracheal explants as an ex vivo model for the study of Middle East respiratory syndrome coronavirus (MERS-CoV) infection

Middle East respiratory syndrome coronavirus (MERS-CoV) poses a serious threat to public health. Here, we established an ex vivo alpaca tracheal explant (ATE) model using an air-liquid interface culture system to gain insights into MERS-CoV infection in the camelid lower respiratory tract. ATE can be infected by MERS-CoV, being 103 TCID50/mL the minimum viral dosage required to establish a productive infection. IFNs and antiviral ISGs were not induced in ATE cultures in response to MERS-CoV infection, strongly suggesting that ISGs expression observed in vivo is rather a consequence of the IFN induction occurring in the nasal mucosa of camelids.info:eu-repo/semantics/publishedVersio